Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Liabilities and Shareholders Equity (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Liabilities and Shareholders Equity data on record, last reported at $11.2 million in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 31.63% year-over-year to $11.2 million; the TTM value through Dec 2025 reached $49.4 million, up 11.92%, while the annual FY2025 figure was $15.6 million, 31.78% up from the prior year.
  • Liabilities and Shareholders Equity reached $11.2 million in Q4 2025 per INM's latest filing, down from $13.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $19.4 million in Q4 2021 and bottomed at $8.5 million in Q4 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $13.6 million, with a median of $13.7 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: crashed 44.27% in 2024, then soared 31.78% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $19.4 million in 2021, then decreased by 12.71% to $16.9 million in 2022, then dropped by 9.84% to $15.3 million in 2023, then plummeted by 44.27% to $8.5 million in 2024, then surged by 31.63% to $11.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $11.2 million in Q4 2025, $13.4 million in Q3 2025, and $15.6 million in Q2 2025.